RAC1-P29S TCT T cells (Anocca AB)

N/A

Report date: 2023/01/07 10:59:49

Base Information

Drug NameRAC1-P29S TCT T cells (Anocca AB)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionRas-related C3 botulinum toxin substrate 1 inhibitors
TargetsRas-related C3 botulinum toxin substrate 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnocca AB
China Registration ClassN/A

Develop Information

Active CompaniesAnocca AB
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A